| Erasca Reports First Quarter 2025 Business Updates and Financial Results |
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2025. “We are pleased with the pace and execution of our RAS-targeting franchise and its early entry into the clinic following the recent IND clearance for ERAS-0015 and IND filing for ERAS-4001,” said Jonathan E. |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway |
IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-0015, a pan-RAS molecular glue with best-in-class potential for patients with RAS-mutant (RASm) solid tumors, and submission of an IND application for ERAS-4001, a potential first-in-class pan-KRAS inhibitor in KRAS-mutant (KRASm) solid tumors. The company also announced a strategic decision to pursue partnership opportunities for naporafenib, enabling a meaningful extension of cash runway guidance from the second half of 2027 to the second half of 2028. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Erasca to Present at the Bank of America Securities Health Care Conference |
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor meetings. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting |
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today presented new preclinical data reinforcing the best-in-class profiles of Erasca's RAS-targeting franchise at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The Company also presented potential first-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly, representing a new approach to block oncogenic RAS/MAPK pathway signaling. |
globenewswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| Erasca, Inc.: Carving A Different Niche In RAS Signaling |
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk. |
seekingalpha.com |
2025-04-25 15:33:45 |
Czytaj oryginał (ang.) |
| Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting |
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025, in Chicago, Illinois. The abstracts will be available on the AACR 2025 meeting website. |
globenewswire.com |
2025-03-25 18:31:00 |
Czytaj oryginał (ang.) |
| Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results |
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 |
globenewswire.com |
2025-03-20 18:01:00 |
Czytaj oryginał (ang.) |
| Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference |
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings. |
globenewswire.com |
2025-01-31 10:00:00 |
Czytaj oryginał (ang.) |
| Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma |
Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors. |
seekingalpha.com |
2025-01-27 02:09:32 |
Czytaj oryginał (ang.) |
| Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) |
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-01-21 12:36:12 |
Czytaj oryginał (ang.) |
| Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround |
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-01-20 12:40:21 |
Czytaj oryginał (ang.) |
| Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) |
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-01-17 12:35:35 |
Czytaj oryginał (ang.) |
| Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) |
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-01-16 12:35:29 |
Czytaj oryginał (ang.) |
| Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-11-15 13:00:45 |
Czytaj oryginał (ang.) |
| Erasca Reports Third Quarter 2024 Business Updates and Financial Results |
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Erasca to Present at Upcoming Investor Conferences |
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. |
globenewswire.com |
2024-11-05 10:00:00 |
Czytaj oryginał (ang.) |
| Erasca Reports Second Quarter 2024 Business Updates and Financial Results |
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors |
globenewswire.com |
2024-08-12 20:01:00 |
Czytaj oryginał (ang.) |
| Should You Buy Erasca, Inc. (ERAS) After Golden Cross? |
After reaching an important support level, Erasca, Inc. (ERAS) could be a good stock pick from a technical perspective. ERAS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. |
zacks.com |
2024-06-04 14:56:25 |
Czytaj oryginał (ang.) |
| Erasca to Present at Upcoming Investor Conferences in June |
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings. |
globenewswire.com |
2024-05-29 12:00:00 |
Czytaj oryginał (ang.) |
| Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares |
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares. All of the shares in the offering were sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, were approximately $184.0 million. |
globenewswire.com |
2024-05-21 20:05:00 |
Czytaj oryginał (ang.) |
| Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal |
SolStock Deals and Financings Japan’s Takeda (TAK, OTCPK:TKPHF; TSE: 4502) acquired global rights to an Alzheimer’s therapy developed by AC Immune SA (ACIU) of Switzerland for $100 million upfront and up to $2.1 billion in milestone payments (see story). With the $100 million, Takeda owns an option to license AC Immune’s active immunotherapies that target toxic forms of amyloid beta (Abeta), including ACI-24.060. ACI-24.060 is an anti-Abeta active immunotherapy candidate aimed at reducing the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. Currently, ACI-24.060 is being tested in a double-blind, placebo-controlled Phase Ib/II trial in subjects with mild Alzheimer’s disease and in adults with Down's syndrome. San Diego’s Erasca (ERAS) acquired rights for two China-developed pre-clinical RAS candidates in two separate agreements, while it is sidelining two of its own candidates and temporarily discontinuing development on a third candidate. Erasca will also raise $160 million from investors. The company acquired ex-China rights to a pan-RAS molecular glue (ERAS-0015) from Joyo Pharmatech of Guangzhou in a $189 million deal and global rights to a pan-KRAS inhibitor (ERAS-4001) from Sichuan Medshine Discovery in a $170 million agreement. Shenzhen Beimei Pharma acquired greater China rights for Twyneo, a therapy for acne vulgaris, from Israel’s Sol-Gel (SLGL) for $15 million. Sol-Gel will be eligible to receive up to $10 million in upfront and regulator milestones. The remaining $5 million is potential royalty payments. Twyneo is the only fixed-dose combination of tretinoin and benzoyl peroxide cream available in the US; it is approved to treat acne vulgaris in adults and pediatric patients. Beimei markets products for pediatrics patients with a portfolio of more than 40 drugs approved or in the pipeline. Trials and Approvals Shanghai’s Zai Lab (ZLAB; HK: 9688) reported China’s NMPA approved Augtyro (repotrectinib) as a treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) (see story). The approval is based on an open-label, single-arm, Phase I/II trial that evaluated repotrectinib in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC. In 2020, Zai Lab acquired China rights to the drug from Turning Point Therapeutics of San Diego for $25 million upfront and up to $151 million in milestones, plus royalties. Turning Point is now a division of Bristol-Myers Squibb (BMY). Shanghai Everest Medicines (HK: 1952) launched Nefecon, a treatment for IgA nephropathy (IgAN), in China by filling the first prescription. IgAN, a rare disease that accounts for 35-50% of glomerular disease cases in China, can cause end-stage renal disease that is treated by kidney replacement or dialysis. Nefecon is a targeted-release formulation of budesonide, a second-generation synthetic corticosteroid. In 2019, Everest acquired greater China rights to the drug from Calliditas Therapeutics (CALT, OTCPK:CLTEF) of Sweden in a $121 million agreement. Nefecon is already approved in the US and EU. Suzhou Ractigen Therapeutics reported that a China IND was approved for RAG-17 as a therapy for Amyotrophic Lateral Sclerosis (ALS). RAG-17 is a therapeutic siRNA designed to suppress the SOD1 gene in ALS patients with pathogenic mutations. Of the more than 50 genes associated with ALS, SOD1 gene mutations account for approximately 20% of the cases. Using Ractigen's proprietary SCAD delivery platform, RAG-17 combines siRNA with an accessory oligonucleotide to improve efficacy in central nervous system tissues. In preclinical studies, RAG-17 showed the ability to improve motor function and prolong survival. Beijing InnoCare Pharma (OTCPK:INCPF; HK: 09969; SHA: 688428) has completed the enrollment process in a China Phase II trial of ICP-488, a potential psoriasis therapy (see story). ICP-488 is a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor. The trial enrolled 129 patients who were randomized to one of three treatment groups in a 1:1:1 ratio: a 6mg once-daily group, a 9mg once-daily group, and a placebo group, for 12 consecutive weeks of treatment. By binding the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines. Shanghai Mabwell (SHA: 688062) reported positive data from a China trial of its novel Nectin-4-targeting ADC for triple-negative breast cancer. In 20 patients with advanced or metastatic disease, 50% reported an objective response and 80% experienced disease control. One patient had a complete response that has continued for 20 months so far. Mabwell says a China IND for the drug, 9MW2821, has also been accepted in combination with an immune checkpoint inhibitor. According to the company, 9MW2821 is the first the Nectin-4-targeting ADC developed by a Chinese company to start clinical trials. Nanjing IASO Bio announced that Science Immunology, a sub-journal of Science, published a single-cell analysis of its anti-BCMA CAR T cell therapy in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune disease that usually occurs in the optic nerve and spinal cord, though it can affect the brain. The disease, which occurs in flare-ups that can cause muscle weakness or blindness, is sometimes misdiagnosed as multiple myeloma. Last year, IASO and its partner, Innovent (OTCPK:IVBIY, OTCPK:IVBXF), were approved in China to launch Equecabtagene Autoleucel, an anti-BCMA CAR T drug, as a fourth-line therapy for multiple myeloma. Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors. |
https://seekingalpha.com |
2024-05-20 05:30:00 |
Czytaj oryginał (ang.) |
| Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise |
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors |
globenewswire.com |
2024-05-17 00:02:00 |
Czytaj oryginał (ang.) |
| Erasca Announces Pricing of Underwritten Offering of Common Stock |
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 12,972,972 shares of common stock at the offering price. The offering is expected to close on May 21, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-05-17 00:00:00 |
Czytaj oryginał (ang.) |
| Erasca Reports First Quarter 2024 Business Updates and Financial Results |
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2024. “We started 2024 strong with compelling survival data from a pooled analysis of mature data for naporafenib plus trametinib in patients with NRAS-mutant (NRASm) melanoma, which showed a near doubling of median overall survival (mOS) versus comparable historical controls,” said Jonathan E. |
globenewswire.com |
2024-05-08 20:01:00 |
Czytaj oryginał (ang.) |
| Erasca to Present at the Bank of America Health Care Conference |
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investor meetings. |
globenewswire.com |
2024-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting |
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer |
globenewswire.com |
2024-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? |
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-04-23 17:00:17 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for April 23rd |
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024. |
zacks.com |
2024-04-23 15:01:12 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 23rd |
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024. |
zacks.com |
2024-04-23 12:16:06 |
Czytaj oryginał (ang.) |
| Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript |
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-29 13:11:07 |
Czytaj oryginał (ang.) |
| Erasca Announces $45 Million Oversubscribed Private Placement Financing |
Funding from new and existing investors extends anticipated cash runway into H2 2026 Funding from new and existing investors extends anticipated cash runway into H2 2026 |
globenewswire.com |
2024-03-27 22:30:00 |
Czytaj oryginał (ang.) |
| Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results |
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 |
globenewswire.com |
2024-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference |
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company on Tuesday, January 9, 2024 at 9:00 am Pacific Time in Elizabethan Room D. Dr. Lim and David M. Chacko, M.D., chief financial officer and chief business officer, will also participate in one-on-one investor meetings. |
globenewswire.com |
2024-01-03 10:00:00 |
Czytaj oryginał (ang.) |